Literature DB >> 23387800

Cytokine profile and FVIII inhibitors development in haemophilia A.

C A Oliveira1, C Velloso-Rodrigues, F C J Machado, B N Carvalho, S H L Gentz, O A Martins-Filho, D G Chaves.   

Abstract

Haemophilia A is a hereditary bleeding disorder linked to the X chromosome characterized by a deficiency or defect in the coagulation factor VIII (FVIII). Individuals with this coagulopathy require constant infusions of FVIII to maintain their physical integrity and haemostasis. During treatment, some patients develop an immune response that produces antibodies to FVIII, also called inhibitors, affecting the pro-coagulant activity of this protein. Despite the clinical relevance of FVIII inhibitors, the immune mechanisms that lead to their production are not known. This study investigated the immunological cytokine profile using plasma from HA patients which were either positive or negative for FVIII inhibitors and from healthy individuals. The results showed that healthy individuals and HA patients that do not develop FVIII inhibitors have a mixed immune response profile with high secretion of IFN-γ, TNF-α IL-2 and IL-5. In contrast, HA patients with FVIII inhibitors exhibited an anti-inflammatory/regulatory immune response characterized by low levels of all measured cytokines except for IL-4 and IL-10. This profile may be related to the development and maintenance of the FVIII inhibitors. By comparing the cytokine profiles of the three different groups we have established a model explaining the immune activation resulting in the production of FVIII inhibitors in haemophilia A patients.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23387800     DOI: 10.1111/hae.12096

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  B cell-activating factor modulates the factor VIII immune response in hemophilia A.

Authors:  Bhavya S Doshi; Jyoti Rana; Giancarlo Castaman; Mostafa A Shaheen; Radoslaw Kaczmarek; John Ss Butterfield; Shannon L Meeks; Cindy Leissinger; Moanaro Biswas; Valder R Arruda
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

2.  The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors.

Authors:  Amanda Co Silveira; Marcio Ap Santana; Isabella G Ribeiro; Daniel G Chaves; Olindo A Martins-Filho
Journal:  BMC Hematol       Date:  2015-01-16

3.  Effectiveness of two psychological interventions for pain management, emotional regulation and promotion of quality of life among adult Portuguese men with haemophilia (PSY-HaEMOPEQ): study protocol for a single-centre prospective randomised controlled trial.

Authors:  Patrícia Ribeiro Pinto; Ana Cristina Paredes; Patrício Costa; Manuela Carvalho; Manuela Lopes; Susana Fernandes; Susana Pedras; Armando Almeida
Journal:  BMJ Open       Date:  2017-09-03       Impact factor: 2.692

4.  Serum TNF-α Level as a Possible Predictor of Inhibitor Levels in Severe Hemophilia A.

Authors:  Susi Susanah; Harry Raspati; Nur Melani Sari; Lulu Eva Rakhmilla; Yunia Sribudiani; Octawyana Moestopo; Puspasari Sinaga; Ponpon Idjradinata; Ani Melani Maskoen
Journal:  Biomed Res Int       Date:  2021-11-05       Impact factor: 3.411

5.  An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs.

Authors:  Junjiang Sun; Wenwei Shao; Xiaojing Chen; Elizabeth P Merricks; Lauren Wimsey; Yasmina L Abajas; Glenn P Niemeyer; Clinton D Lothrop; Paul E Monahan; R Jude Samulski; Timothy C Nichols; Chengwen Li
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-04       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.